Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Extended-Release Niacin/Laropiprant/Simvastatin (Tredaptive) in Primary Hypercholesterolemia or Mixed Dyslipidemia
2010-023939-42Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of laropiprant in hypercholesterolemia, combined dyslipidaemia and dyslipidemia (2 arms), sponsored by Merck & Co. Primary endpoint: Primary endpoint (HDL-C). Started Mar 2011; status: completed.
02
Drugs
laropiprant
03
Conditions
hypercholesterolemiacombined dyslipidaemiadyslipidemia
Beyond the preview
Go deeper on 2010-023939-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023939-42.